Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2026)
Xilio Therapeutics (XLO) posted Current Deferred Revenue of $31.5 million for Q1 2026, down 21.19% sequentially from $40.0 million in Q4 2025, and down 60.07% YoY from $79.0 million in Q1 2025.
Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Xilio Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $31.5 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 60.07% year-over-year to $31.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.5 million (down 60.07% YoY) and the FY2025 annual result came in at $40.0 million, up 196.07% from the prior year.
- Current Deferred Revenue slipped to $31.5 million in Q1 2026 per XLO's latest filing, from $40.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $79.0 million in Q1 2025 and troughed at $13.5 million in Q4 2024.
- A 3-year average of $38.9 million and a median of $31.5 million in 2026 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue surged 263.61% in 2025, then plunged 60.07% in 2026.
- Over 3 years, Current Deferred Revenue stood at $13.5 million in 2024, then surged by 196.07% to $40.0 million in 2025, then slipped by 21.19% to $31.5 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $31.5 million, $40.0 million, and $69.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.32 Mn |
| Mar 31, 2026 | 31.54 Mn |
| Dec 31, 2025 | 40.02 Mn |
| Sep 30, 2025 | 69.34 Mn |
| Jun 30, 2025 | 42.28 Mn |
| Mar 31, 2025 | 78.99 Mn |
| Dec 31, 2024 | 13.52 Mn |
| Sep 30, 2024 | 26.11 Mn |
| Jun 30, 2024 | 26.52 Mn |
| Mar 31, 2024 | 21.73 Mn |